ProSkelia Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 65

Employees

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 3

ProSkelia General Information

Description

Provider of drug discovery and development intended to treat bone diseases. The company's portfolio of technology includes an exclusive program named oestradiol glucoside ("E2G"), which completed a Phase IIa clinical study for the treatment of menopausal symptoms, along with drugs related to the preclinical development and in vivo pharmacology.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • 102 route de Noisy
  • 93230 Romainville
  • France
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 102 route de Noisy
  • 93230 Romainville
  • France

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ProSkelia Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ProSkelia‘s full profile, request access.

Request a free trial

ProSkelia Patents

ProSkelia Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-1313753-A2 Regulator gene and system useful for the diagnosis and therapy of osteoporosis Inactive 18-Aug-2000

ProSkelia Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ProSkelia Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ProSkelia‘s full profile, request access.

Request a free trial

ProSkelia FAQs

  • When was ProSkelia founded?

    ProSkelia was founded in 2002.

  • Where is ProSkelia headquartered?

    ProSkelia is headquartered in Romainville, France.

  • What is the size of ProSkelia?

    ProSkelia has 65 total employees.

  • What industry is ProSkelia in?

    ProSkelia’s primary industry is Drug Discovery.

  • Is ProSkelia a private or public company?

    ProSkelia is a Private company.

  • What is the current valuation of ProSkelia?

    The current valuation of ProSkelia is .

  • What is ProSkelia’s current revenue?

    The current revenue for ProSkelia is .

  • Who are ProSkelia’s investors?

    Kyowa Kirin International has invested in ProSkelia.

  • When was ProSkelia acquired?

    ProSkelia was acquired on 22-Dec-2006.

  • Who acquired ProSkelia?

    ProSkelia was acquired by Lakefront Biotherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process